Traws Pharma ( ($TRAW) ) just unveiled an update. Traws Pharma, Inc. announced the appointment of Iain Dukes as the Interim Chief Executive ...

Roche Diagnostics promoted Johnny Smith to global head of communications. Traws Pharma announced Iain D. Dukes, D Phil, its executive board chairman, will become interim CEO. Kevin Ciemniecki returned ...

NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...

Traws Pharma Inc. (TRAW) saw a 4.16% increase in its stock price following its Q1 2025 earnings call, reflecting positive investor sentiment driven by promising updates in its antiviral drug pipeline.

Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing ...

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates - (March 24, 2025) Traws Pharma, Inc. today announced positive topline results from a study ...

TRAWS PHARMA ($TRAW) posted quarterly earnings results on Monday, March 31st. The company reported earnings of $95.66 per share, beating estimates of -$9.74 by $105. ...